Publications by authors named "Angela Grove"

Purpose: Infusion-related hypersensitivity reactions with paclitaxel are common despite the use of dexamethasone and diphenhydramine premedications. Paclitaxel titration protocols that may reduce reactions are empirically derived from clinical observations, and there are no phase III trials that confirm superiority of any management recommendations. The purpose of this study was to compare the frequency and severity of hypersensitivity reactions associated with a recently initiated standardized paclitaxel titration protocol verses standard-of-care (SOC) infusion protocols.

View Article and Find Full Text PDF

Immune checkpoint inhibitors (ICIs) can cause a variety of immune-related adverse events (irAEs). The coronavirus disease 2019 (COVID-19) is associated with increased amounts of pro-inflammatory cytokines, which may affect the outcome of irAEs. Data are limited regarding the impact of COVID-19 on irAEs in ICI-treated cancer patients.

View Article and Find Full Text PDF

There is limited data on the use of caplacizumab beyond the initial treatment course. We describe a patient case demonstrating the efficacy of a second course of caplacizumab in a patient with relapsed acquired thrombotic thrombocytopenic purpura (TTP). A 25-year-old female was treated for an initial event of TTP with steroids, plasma exchange, rituximab, and caplacizumab.

View Article and Find Full Text PDF